Neuropsychiatric Complications and Psychopharmacology of End-Stage Renal Disease

Therapy in Nephrology & Hypertension

Volumn , Issue , 2008, Pages 795-817

  Mirot, Adam M ^a,b   Tessier, Edward G ^c,d   Germain, Michael J ^e   Cohen, Lewis M ^e  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYSTATE MEDICAL CENTER   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d Baystate Franklin Medical Center   (United States)

^e TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862158259     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141605484-9.50075-7     Document Type: Chapter

References (151)

1. USRDS Excerpts from the United States Renal Data System 2000 Annual Data Report. National Institutes of Health NIDDK/DKUHD. Am J Kidney Dis 2000, 36(Suppl 2):S1-S239.
2. Fraser CL, Arieff AI Neuropsychiatric complications of renal failure. Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector-s The Kidney 2001, 488-490. WB Saunders, Philadelphia. H.R. Brady, C.S. Wilcox (Eds.).
3. Tzamaloukas AH, Agaba ET Neurological manifestations of uraemia and chronic dialysis. Niger J Med 2004, 13:98-105.
4. Fraser CL, Arieff AI Metabolic encephalopathy as a complication of renal failure: Mechanisms and mediators. New Horiz 1994, 2:518-526.
5. Palmer BF, Henrich WL Uremic mononeuropathy. UpToDate 2001, UpToDate, Wellesley, MA. http://www.uptodate.com, B.D. Rose (Ed.).
6. Krishnan AV, Phoon RK, Pussell BA, et al. Sensory nerve excitability and neuropathy in end stage kidney disease. J Neurol Neurosurg Psychiatry 2006, 77:548-551.
7. Krishnan AV, Kiernan MC Uremic neuropathy: Clinical features and new pathophysiological insights. Muscle Nerve 2007, 35:273-290.
8. Barri YM, Golper TA Seizures in patients undergoing hemodialysis polyneuropathy. UpToDate 2001, UpToDate, Wellesley, MA. http://www.uptodate.com, B.D. Rose (Ed.).
9. Lacerda G, Krummel T, Sabourdy C, et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006, 67(Suppl 4):S28-S33.
10. Abou Khaled KJ, Hirsch LJ Advances in the management of seizures and status epilepticus in critically ill patients. Crit Care Clin 2006, 22:637-659.
11. Arieff AI Dialysis disequilibrium syndrome: Current concepts on pathogenesis and prevention. Kidney Int 1994, 45:629-635.
12. Walker S, Fine A, Kruger MH Sleep complaints are common in a dialysis unit. Am J Kidney Dis 1995, 26:751-756.
13. Kimmel PL, Gavin C, Miller G, et al. Disordered sleep and noncompliance in a patient with end-stage renal disease. Adv Ren Replace Ther 1997, 4:55-67.
14. Levy NB Psychiatric consideration in the primary medical care of the patient with renal failure. Adv Ren Replace Ther 2000, 7:231-238.
15. Noda A, Nakai S, Soga T, et al. Factors contributing to sleep disturbance and hypnotic drug use in hemodialysis patients. Intern Med 2006, 45:1273-1278.
16. Jurado-Gamez B, Martin-Malo A, Alvarez-Lara MA, et al. Sleep disorders are underdiagnosed in patients on maintenance dialysis. Nephron Clin Pract 2007, 105:c35-c42.
17. Novak M, Shapiro CM, Mendelssohn D, Istvan M Diagnosis and management of insomnia in dialysis patients. Semin Dial 2006, 199:25-31.
18. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007, 356:29-38.
19. Thorp ML, Morris CD, Bagby SP A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001, 38:104-108.
20. Wagner ML, Walters AS, Coleman RG, et al. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep 1996, 19:52-58.
21. Pieta J, Millar T, Zacharias J, et al. Effect of pergolide on restless legs and leg movements in sleep in uremic patients. Sleep 1998, 21:617-622.
22. Molnar MZ, Novak M, Musci I Management of restless legs syndrome in patients on dialysis. Drugs 2006, 66:607-624.
23. Sloand JA, Shelly MA, Feigin A, et al. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004, 43:663-670.
24. Fletcher EC Obstructive sleep apnea and the kidney. J Am Soc Nephrol 1993, 4:1111-1121.
25. Fein AM, Niederman MS, Imbriano L, Rosen H Reversal of sleep apnea in uremia by dialysis. Arch Intern Med 1987, 147:1355-1356.
26. Langevin B, Fouque D, Leger P, Robert D Sleep apnea syndrome and end-stage renal disease. Cure after renal transplantation. Chest 1993, 103:1330-1335.
27. Shayamsunder AK, Patel SS, Jain V, et al. Sleepniness, sleeplessness, and pain in end-stage renal disease: Distressing symptoms for patients. Semin Dial 2005, 18:109-118.
28. Hanly PJ, Pierratos A Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001, 344:102-107.
29. Karasek M, Szuflet A, Chrzanowski W, et al. Decreased melatonin nocturnal concentrations in hemodialyzed patients. Neurol Endocrinol Lett 2005, 26:653-656.
30. Rothschild AJ Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: A review of the literature. J Clin Psychiatry 1992, 53(Suppl):69-79.
31. Mendelson WB, Jain B An assessment of short-acting hypnotics. Drug Saf 1995, 3:257-270.
32. Drover DR Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: Zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 2004, 43:227-238.
33. Sabbatini M, Crispo A, Ragosta A, et al. Zaleplon improves sleep quality in maintenance hemodialysis patients. Nephron Clin Pract 2003, 94:c99-c103.
34. James SP, Mendelson WB The use of trazodone as a hypnotic: A critical review. J Clin Psychiatry 2004, 65:752-755.
35. Fukunishi I, Kitaoka T, Shirai T, et al. Delirium in patients on hemodialysis therapy. Nephron 2002, 90:236.
36. Revenkar SG, Applegate AL, Markovitz DM Delirium associated with acyclovir treatment in a patient with renal failure. Clin Infect Dis 1995, 21:435-436.
37. Stock SL, Catalono G, Catallano MC Meperidine associated mental status changes in a patient with chronic renal failure. J Fla Med Assoc 1996, 83:315-319.
38. Steinman MA, Steinman TI Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996, 27:143-146.
39. Neely KJ, Roxe DM Palliative care/hospice and the withdrawal of dialysis. J Palliat Med 2000, 3:57-67.
40. Cassem NH, Hackett TP The setting of intensive care. Massachusetts General Hospital Handbook of General Hospital Psychiatry 1978, 326-327. CV Mosby, St. Louis. T.P. Hackett, N.H. Cassem (Eds.).
41. Schmidt RJ, Holley JL Psychiatric illness in dialysis patients. UpToDate 2001, UpToDate, Wellesley, MA. http://www.uptodate.com, B.L. Rose (Ed.).
42. Sithinamsuwan P, Niyasom S, Nidhinandana S, Supasyndh O Dementia and depression in end stage renal disease: Comparison between hemodialysis and continuous ambulatory peritoneal dialysis. J Med Assoc Thai 2005, 88(Suppl 3):S141-S147.
43. Hung SC, Hung SH, Tarng DC, et al. Thiamine deficiency and unexplained encephalopathy in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2001, 38:941-947.
44. Brouns R, De Deyn PP Neurological complications in renal failure: A review. Clin Neurol Neurosurg 2004, 107:1-16.
45. Sengul G, Tuzun Y, Kadioglu HH, Aydin IH Acute interhemispheric subdural hematoma due to hemodialysis: Case report. Surg Neurol 2005, 64(Suppl 2):S113-S114.
46. Suwata J, Kamata K, Nishijima T, et al. New acetylcholinesterase inhibitor (donepezil) treatment for Alzheimer-s disease in chronic dialysis patient. Nephron 2002, 91:330-332.
47. Seltzer B Donepezil: A review. Expert Opin Drug Metab Toxicol 2005, 1:527-536.
48. Reiss D Patient, family and staff responses to end-stage renal disease. Am J Kidney Dis 1990, 15:194-200.
49. Thong MSY, Adrian A, Kapstein R, et al. Social support predicts survival in dialysis patients. Nephrol Dial Transplant 2007, 22:845-850.
50. Levy NB Sexual dysfunctions of hemodialysis patients. Clin Exp Dial Apheresis 1983, 7:275-288.
51. O-Donnell K, Chung Y The diagnosis of major depression in end-stage renal disease. Psychosomatics 1997, 66:38-43.
52. Finkelstein FO, Finkelstein SH Depression in chronic dialysis patients: Assessment and treatment. Nephrol Dial Transplant 2000, 15:191-192.
53. Haenel T, Brunner F, Battegay R Renal dialysis and suicide: Occurrence in Switzerland and Europe. Compr Psychiatry 1980, 21:140-145.
54. Cohen LM, Steinberg MD, Hails KC, et al. The psychiatric evaluation of death-hastening requests: Lessons from dialysis discontinuation. Psychosomatics 2000, 41:195-203.
55. Kimmel PL, Peterson RA, Weihs KL, et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int 2000, 57:2093-2098.
56. Shulman R, Price JD, Spinelli J Biopsychosocial aspects of long-term survival on end-stage renal failure therapy. Psychol Med 1989, 19:945-954.
57. Levy NB, Cohen LM Central and peripheral nervous systems in uremia. Textbook of Nephrology 2001, 1279-1282. Williams & Wilkins, Philadelphia. 4 ed. S.G. Massry, R. Glassock (Eds.).
58. Wuerth D, Finkelstein SH, Finkelstein FO The identification and treatment of depression in patients maintained on dialysis. Semin Dial 2005, 18:142-146.
59. Blumenfield M, Levy NB, Spinowitz B, et al. Fluoxetine in depressed patients on dialysis. Int J Psychiatry Med 1997, 27:71-80.
60. Dheenan S, Venketesan J, Grubb BP, Henrich WL Effect of sertraline hydrochloride on dialysis hypotension. Am J Kidney Dis 1998, 31:624-630.
61. Joffe P, Larsen FS, Pedersen V, et al. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with health subjects. Eur J Clin Pharmacol 1998, 54:237-242.
62. Doyle CD, Laher M, Kelly JG, et al. The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatr Scand 1989, 80(Suppl 350):89-90.
63. Troy SM, Schultz RW, Parker VD, et al. The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther 1994, 56:14-21.
64. Crone CC, Gabriel GM Treatment of anxiety and depression in transplant patients: Pharmacokinetic considerations. Clin Pharmacokinet 2004, 43:361-394.
65. Timmer CJ, Ad Sitsen JM, Delbressine LP Clinical pharmacokinetics of mirtazepine. Clin Pharmacokinet 2000, 38:461-474.
66. Seabolt JL, DeLeon OA Response to nefzaodone in a depressed patient with end-stage renal disease. Gen Hosp Psychiatr 2001, 23:45-46.
67. Aronoff GR, Berns JS, Brier ME, et al. Drug Prescribing in Renal Failure. Dosing Guidelines for Adults 1999, American College of Physicians-American Society for Internal Medicine, Philadelphia. 4th ed.
68. Brater DC Drug Dosing in Renal Failure in Therapy in Nephrology and Hypertension. A Companion to Brenner and Rector-s The Kidney 2001, 641-653. WB Saunders, Philadelphia.
69. Port FK, Kroll PD, Rosenzweig J Lithium therapy during maintenance hemodialysis. Psychosomatics 1979, 20:130-132.
70. Braden GL Lithium-induced renal disease. Primer on Kidney Disease 2001, 322-324. Academic Press, San Diego, CA. 3rd ed. A. Greenberg, T.M. Coffman, A.K. Cheung (Eds.).
71. Williams S, Ostroff R Chronic renal failure, hemodialysis, and electroconvulsive therapy: A case report. J ECT 2005, 21:41-42.
72. Varghese ST, Sagar R, Jhanjee S Chronic renal failure and electroconvulsive therapy. Indian J Med Sci 2006, 60:114-115.
73. Lieberman JA, Stroup TS, McAvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. N Engl J Med 2005, 353:1209-1223.
74. Railton CJ, Kapur B, Koren G Subtherapeutic risperidone serum concentrations in an adolescent during hemodialysis: A pharmacological puzzle. Ther Drug Monit 2005, 27:558-561.
75. Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl) 1995, 122:223-229.
76. Aweeka F, Jayesekara D, Horton M, et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br J Clin Pharmacol 2000, 49(Suppl 1):27S-33S.
77. Thyrum PT, Wong YW, Yeh C Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry 2000, 24:521-533.
78. Fukunishi I, Sato Y, Kino K, et al. Hypothermia in a hemodialysis patient treated with olanzapine monotherapy. J Clin Psychopharmacol 2003, 23:314.
79. Fraser D, Jibani M An unexpected and serious complication of treatment with the atypical antipsychotic drug clozapine. Clin Nephrol 2000, 54:78-80.
80. Haddad PM, Anderson IM Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002, 62:1649-1671.
81. Swainston HT, Perry CM Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs 2004, 64:1715-1736.
82. Hoehns JD, Stanford RH, Geraets DR, et al. Torsades de pointes associated with chlorpromazine: Case report and review of associated ventricular arrhythmias. Pharmacotherapy 2001, 21:871-883.
83. Peng Y-S, Chiang C-K, Hung K-Y, et al. The association of higher depressive symptoms and sexual dysfunction in male haemodialysis patients. Nephrol Dial Transplant 2007, 22:857-861.
84. Soykan A, Boztas H, Kutlay S, et al. Do sexual dysfunctions get better during dialysis? Results of a six-month prospective follow-up study from Turkey. Int J Impot Res 2005, 17:359-363.
85. Palmer BF Sexual dysfunction in men and women with chronic kidney disease and end-stage kidney disease. Adv Ren Replace Ther 2003, 10:48-60.
86. Turk S, Karalezli G, Tonbul HZ, et al. Erectile dysfunction and the effects of sildenafil treatment in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2001, 16:1818-1822.
87. Hyodo T, Ishida H, Masui N, et al. Kidney disease quality of life of Japanese dialysis patients who desire administration of sildenafil and the treatment of erectile dysfunction using sildenafil. Ther Apher Dial 2004, 8:340-346.
88. Dachille G, Pagliarulo V, Ludovico GM, et al. Sexual dysfunction in patients under dialytic treatment. Minerva Urol Nephrol 2006, 58:195-200.
89. Spigset O, Hagg S, Stegmayr B, Dahlqvist R Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Eur J Clin Pharmacol 2000, 56:699-703.
90. Drewes P, Thijssen I, Mengel H, et al: A single-dose cross-over pharmacokinetic study comparing racemic citalopram (40 mg) with the S-enantiomer of citalopram (escitalopram, 20 mg) in healthy male subjects. Presented at the Annual Meeting of New Clinical Drug Evaluation Unit, Phoenix, AZ, 2001.
91. Momen MN, Sebastian CS, Buckley PF Paradoxical reaction to fluoxetine. Psychosomatics 2003, 44:259-260.
92. Kamo T, Horikawa N, Tsuruta Y, et al. Efficacy and pharmacokinetics of fluvoxamine maleate in patients with mild depression undergoing hemodialysis. Psychiatry Clin Neurosci 2004, 58:133-137.
93. Koo JR, Yoon JY, Joo MH, et al. Treatment of depression and effect of antidepression treatment on nutritional status in chronic hemodialysis patients. Am J Med Sci 2005, 329:1-5.
94. Brewster UC, Ciampi MA, Abu-Alfa AK, Perazella MA Addition of sertraline to other therapies to reduce dialysis-associated hypotension. Nephrology 2003, 8:296-301.
95. Yalcin AU, Kudaiberdieva G, Sahin G, et al. Effect of sertraline hydrochloride on cardiac autonomic dysfunction in patients with hemodialysis-induced hypotension. Nephron Physiol 2003, 93:21-28.
96. Yalcin AU, Sahin G, Erol M, Bal C Sertraline hydrochloride treatment for patients with hemodialysis hypotension. Blood Purif 2002, 20:150-153.
97. Perazella MA Pharmacologic options available to treat symptomatic intradialytic hypotension. Am J Kidney Dis 2001, 38(4 Suppl 4):S26-S36t.
98. Degen J, Wolke E, Seiberling M, et al. [Comparative study of the pharmacokinetics of amitriptyline oxide and trimipramine after single administration in healthy male probands and patients with renal failure]. Med Klin 1993, 88:129-133.
99. Lieberman JA, Cooper TB, Suckow RF, et al. Tricyclic antidepressant and metabolite levels in chronic renal failure. Clin Pharmacol Ther 1985, 37:301-307.
100. Kennedy SH, Craven JL, Rodin GM Major depression in renal dialysis patients: An open trial of antidepressant therapy [erratum appears in J Clin Psychiatry 1989;50:148]. J Clin Psychiatry 1989, 50:60-63.
101. Sunderrajan S, Brooks CS, Sunderrajan EV Nortriptyline-induced severe hyperventilation. Arch Intern Med 1985, 145:746-747.
102. Sandoz M, Vandel S, Vandel B, et al. Metabolism of amitriptyline in patients with chronic renal failure. Eur J Clin Pharmacol 1984, 26:227-232.
103. Dawlilng S, Lynn K, Rosser R, Braithwaite R The pharmacokinetics of nortriptyline in patients with chronic renal failure. Br J Clin Pharmacol 1981, 12:39-45.
104. Worrall SP, Almond MK, Dhillon S Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke. A single dose study. Nephron 2004, 97:c83-c89.
105. Product information. Cymbalta capsules, duloxetine hydrochloride capsules 2004, 2007, Eli Lilly and Company, Indianapolis, IN.
106. Bymaster FP, Lee TC, Knadler MP, et al. The dual transporter inhibitor duloxetine: A review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 2005, 11:1475-1493.
107. Bennett WM, Aronoff GR, Golper TA, et al. Drug Prescribing in Renal Failure 1994, American College of Physicians, Philadelphia. 3rd ed.
108. Fukunishi I, Kitaoka T, Shirai T, Watanabe S Cardiac arrest caused by maprotiline in an elderly hemodialysis patient. Nephron 1998, 78:225.
109. Fukunishi I, Kitaoka T, Shirai T, et al. A hemodialysis patient with trazodone-induced parkinsonism. Nephron 2002, 90:222-223.
110. Catanese B, Dionisio A, Barillari G A comparative study of trazodone serum concentration in patients with normal or impaired renal function. Boll Chim Farm 1978, 117:424-427.
111. Walcher J, Schoecklmann H, Renders L Lithium acetate therapy in a maintenance hemodialysis patient. Kidney Blood Pressure Res 2004, 27:200-202.
112. Moreiras Plaza M, Rodriguez Goyanes G, Cuina L, Alonso R On the toxicity of valproic-acid. Clin Nephrol 1999, 51:187-189.
113. Dorson PG, Crismon ML Chlorpromazine accumulation and sudden death in a patient with renal insufficiency. Drug Intell Clin Pharm 1988, 22:776-778.
114. McAllister CJ, Scowden EB, Stone WJ Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure. Clin Nephrol 1978, 10:191-195.
115. Sanga M, Shigemura J Pharmacokinetics of haloperidol in patients on hemodialysis. Nihon Shinkei Seishin Yakurigaku Zasshi 1998, 18:45-47.
116. Schaber G, Stevens I, Gaertner HJ, et al. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: Plasma protein binding and renal clearance. Br J Clin Pharmacol 1998, 46:453-459.
117. Product information. Abilify oral tablets, disintegrating tablets, solution, aripiprazole oral tablets, disintegrating tablets, solution 2006, Bristol-Myers Squibb Company, Princeton, NJ.
118. Product information. Seroquel oral tablets, quetiapine fumarate oral tablets 2006, AstraZeneca Pharmaceuticals, LP, Wilmington, DE,.
119. Railton CJ, Kapur B, Koren G Subtherapeutic risperidone serum concentrations in an adolescent during hemodialysis: A pharmacological puzzle. Ther Drug Monit 2005, 27:558-561.
120. Schmith VD, Piraino B, Smith RB, Kroboth PD Alprazolam in end-stage renal disease. II. Pharmacodynamics. Clin Pharmacol Ther 1992, 51:533-540.
121. Mahmood I, Sahajwalla C Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet 1999, 36:277-287.
122. Joy MS Clonazepam: Benzodiazepine therapy for the restless legs syndrome. ANNA J 1997, 24:686-689.
123. Swart EL, de Jongh J, Zuideveld KP, et al. Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. Am J Kidney Dis 2005, 45:360-371.
124. Product information. Lunesta, eszopiclone 2005, Sepracor, Marlborough, MA.
125. Product information. Sonata oral capsules, zaleplon oral capsules 2004, King Pharmaceuticals, Inc, Bristol, TN.
126. Product information. Ambien oral tablets, zolpidem tartrate oral tablets 2007, Sanofi-Aventis US, LLC, Bridgewater, NJ.
127. Product information. Rozerem tablets, ramelteon tablets 2005, Takeda Pharmaceuticals America, Inc., Lincolnshire, IL.
128. Kandrotas RJ, Oles KS, Gal P, Love JM Carbamazepine clearance in hemodialysis and hemoperfusion. DICP 1989, 23:137-140.
129. Dogukan A, Aygen B, Berilgen MS, et al. Gabapentin-induced coma in a patient with renal failure. Hemodial Int 2006, 10:168-169.
130. Manenti L, Vaglio A, Costantino E, et al. Gabapentin in the treatment of uremic itch: An index case and a pilot evaluation. J Nephrol 2005, 18:86-91.
131. Zhang C, Glenn DG, Bell WL, O-Donovan CA Gabapentin-induced myoclonus in end-stage renal disease. Epilepsia 2005, 46:156-158.
132. Gunal AI, Ozalp G, Yoldas TK, et al. Gabapentin therapy for pruritus in haemodialysis patients: A randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004, 19:3137-3139.
133. Micozkadioglu H, Ozdemir FN, Kut A, et al. Gabapentin versus levodopa for the treatment of restless legs syndrome in hemodialysis patients: An open-label study. Ren Fail 2004, 26:393-397.
134. Penumalee S, Kissner PZ, Migdal SD Gabapentin-induced hypoglycemia in a long-term peritoneal dialysis patient. Am J Kidney Dis 2003, 42:E3-E5.
135. Jones H, Aguila E, Farber HW Gabapentin toxicity requiring intubation in a patient receiving long-term hemodialysis. Ann Intern Med 2002, 137:74.
136. Bassilios N, Launay-Vacher V, Khoury N, et al. Gabapentin neurotoxicity in a chronic haemodialysis patient. Nephrol Dial Transplant 2001, 16:2112-2113.
137. Blum RA, Comstock TJ, Sica DA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 1994, 56:154-159.
138. McBryde KD, Wilcox J, Kher KK Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient. Pediatr Nephrol 2005, 20:1182-1185.
139. Lau AH, Kronfol NO Effect of continuous hemofiltration on phenytoin elimination. Ther Drug Monit 1994, 16:53-57.
140. Porto I, John EG, Heilliczer J Removal of phenobarbital during continuous cycling peritoneal dialysis in a child. Pharmacotherapy 1997, 17:832-835.
141. Product information. Lyrica, pregabalin 2005, Pfizer, New York, NY.
142. Randinitis EJ, Posvar EL, Alvey CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003, 43:277-283.
143. Pellecchia MT, Vitale C, Sabatini M, et al. Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: An open randomized crossover trial versus levodopa sustained release. Clin Neuropharmacol 2004, 27:178-181.
144. Janzen L, Rich JA, Vercaigne LM An overview of levodopa in the management of restless legs syndrome in a dialysis population: Pharmacokinetics, clinical trials, and complications of therapy. Ann Pharmacother 1999, 33:86-92.
145. Wootton R, Soul-Lawton J, Rolan PE, et al. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Br J Clin Pharmacol 1997, 43:23-27.
146. Product information. Lamictal, lamotrigine 2004, GlaxoSmithKline, Research Triangle Park, NC.
147. Cohen LM, Levy NB, Tessier E, Germain M Renal disease. Textbook of Psychosomatic Medicine 2005, 483-493. American Psychiatric Publishing, Washington, DC. J.L. Levenson (Ed.).
148. Finkelstein FO, Finkelstein SH Depression in chronic dialysis patients: Assessment and treatment. Nephrol Dial Transplant 2000, 15:191-192.
149. Kimmel PL, Tharner M, Richard CM, et al. Psychiatric illness in patients with end-stage renal disease. Am J Med 1998, 105:214-221.
150. Levy NB Psychiatric considerations in the primary medical care of the patient with renal failure. Adv Ren Replace Ther 2000, 7:231-238.
151. Novak M, Shapiro CM, Mendelssohn D, Istvan M Diagnosis and management of insomnia in dialysis patients. Semin Dial 2006, 199:25-31.